Vincent Michael Figueredo, MD, FACC, FAHA

Transcription

Vincent Michael Figueredo, MD, FACC, FAHA
Cardiology Division, Albert Einstein Medical Center
Present Appointments
1/07
Director, Cardiovascular Diseases Fellowship Programs, Albert Einstein Medical Center,
Phil., PA
6/06
Associate Professor of Medicine, Jefferson Medical College, Philadelphia, PA
7/05
Faculty, Cardiology Division, Albert Einstein Medical Center, Philadelphia, PA
4/07
Associate, Center for Urban Health Policy and Research, Philadelphia, PA
10/09
Director, Cardiac Rehabilitation Program, Albert Einstein Medical Center, Philadelphia,
PA
Past Appointments
7/05-12/06
Medical Director, Cardiac Imaging of Northeast Philadelphia, PA
7/05-12/06
Faculty, Department of Medicine, Frankford Hosp., Jefferson Health System, Phil., PA
7/05-12/06
Medical Staff, Nazareth Hospital, Philadelphia, PA
7/05-12/06
Member, Greater Philadelphia Cardiology Associates, Philadelphia, PA
8/03-6/05
Chair, Cardiology & Cardiothoracic Surgery Department, Lovelace Health Systems, NM
1/01-6/05
Clinical Associate Professor of Medicine, Univ. of New Mexico Health Sciences Center
11/00-6/05
Director, Lipid Management Program, Heart & Vascular Center, Lovelace Clinic, NM
7/98-6/05
Director, Echocardiography Lab (ICAEL accredited), Lovelace Health Systems, NM
7/98-6/05
Director, Clinical Research, Heart & Vascular Center, Lovelace Health Systems, NM
7/98-1/01
Clinical Assistant Professor of Medicine, Univ of New Mexico Health Sciences Center
7/96-6/98
Affiliated Member, Ernest Gallo Clinic and Research Center, SF, CA
7/96-6/98
Director, Echocardiography Laboratory, San Francisco General Hospital
7/96-6/98
Faculty Investigator, San Francisco Injury Center at SF General Hospital
7/94-6/98
Assistant Professor of Medicine in Residence, Univ. of California, San Francisco
7/94-6/98
Attending Physician, Dept. of Medicine (Cardiology), SF General Hospital
7/94-6/98
Attending Physician, Dept. of Medicine (Cardiology), SF VA Hospital
Postgraduate Training
7/92-6/94
Clinical Fellow in Cardiology; University of California, San Francisco, CA
7/90-6/92
Research Fellow; Cardiovascular Research Institute, UCSF, San Francisco, CA
6/87-6/90
Resident and Intern, Internal Medicine; Columbia Presbyterian Medical Center, NY
Education
7/83-5/87
8/79-6/83
M.D.; College of Physicians & Surgeons, Columbia University, New York, NY
B.A.; Chemistry; Haverford College, Haverford, PA
Professional Qualifications
Medical Licenses: CA G068066; NM 98-55; NY 177224; PA MD426336
Diplomat, National Board of Medical Examiners: 7/1/1988
Diplomat, American Board of Internal Medicine: 9/12/1990
Diplomat, ABIM, Cardiovascular Disease Subspecialty: 11/8/1995; recertification 11/7/2005
Board Certified Specialist in Clinical Hypertension, American Society of Hypertension: 8/9/2001
Diplomat, Certification Board of Nuclear Cardiology: 10/25/2006
Diplomat, Adult Comprehensive Echocardiography, National Board of Echocardiography: 6/30/07
Figueredo, V.M.
Society Memberships
Fellow, American College of Cardiology
Fellow, American Heart Association
Fellow, American Society of Echocardiography
Board Member, Delaware Valley Echo Society (American Society of Echocardiography Chapter)
Board Member, Nuclear Cardiology Working Group of the Delaware Valley (American Society of
Nuclear Cardiology Chapter)
Philadelphia Lipid and Atherosclerosis Club
Northeast Lipid Association (Chapter of the National Lipid Association)
Research Grants and Scholarships
1982
IBM Corporation, Student Research Scholarship Award
1990-1992
NIH, National Research Scholarship Award
1992-1993
Medical School Grant, Merck & Company
1994-1995
University of California, Faculty Development Award
1994-1996
American Heart Association, California Affiliate, Grant-in-Aid
1994-1999
NIH, Clinical Investigator Development Award
1996-1998
American Beverage Medical Research Foundation Grant
1996-2001
NIH, RO1 AA 11135-01
1998-2000
Int'l Collaboration Grant-in-aid for Scientific Research, Ministry of Education of Japan
2000-2001
Grant-in-Aid for Scientific Research, Ministry of Education of Japan
2002-2004
Int'l Collaboration Grant-in-aid for Scientific Research, Ministry of Education of Japan
2004-2006
Grant-in-Aid for Scientific Research, Ministry of Education of Japan (co-investigator)
2006-2007
Grant-in-Aid for Scientific Research, 18592210, Ministry of Education, Culture, Sports,
Science and Technology of Japan (co-investigator)
2007-2009
Pennsylvania Department of Health Commonwealth Universal Research Enhancement
(C.U.R.E.). Program. “Exercise, Metabolic & Inflammatory Processes in Postmenopausal
Minority Women” (consultant).
2008-2009
CV Therapeutics. “Effects of Ranolazine on Diastolic Function in Angina Patients”.
(principal investigator)
2008-2010
(C.U.R.E.) Program. “Feasibility of Adopting the Mediterranean Diet to Modify Risk
factors Associated with Metabolic Syndrome in Older African American Women” (coprincipal investigator)
2008-2009
Awarded by the Albert Einstein Society, Philadelphia, PA. Supplemental funds for
“Feasibility of Adopting the Mediterranean Diet to Modify Risk factors Associated with
Metabolic Syndrome in Older African American Women” (co-principal investigator)
2008-2011
Grant-in-Aid for Scientific Research, Ministry of Education, Culture, Sports, Science and
Technology of Japan (co-investigator)
2009-2010
(C.U.R.E.) Program. “The Use of Telephone Support to Modify Risk Factors Associated
with Metabolic Syndrome Using the Mediterranean Diet in Older African American
Women” (co-principal investigator)
2009-2010
Einstein Society Grant. "Incidence, Characteristics and Prognosis of Transient
Myocardial Dysfunction in Critically Ill Patients.” (principal investigator)
Patents
System for Transmitting Video Images Over a Computer Network to a Remote Receiver. Inventors: VM
Figueredo, KA Roman, PR Raposa, RS Neale, CJ Hoomani, TJ Broadbent. U.S. Patent 7,257,158.
2
Figueredo, V.M.
Teaching Activities
UCSF Dept. of Medicine Core Curriculum Series for Housestaff
UCSF Dept. of Medicine, Primary Care Intern Lecture Series
UCSF Dept. of Medicine Core Curriculum Series for Cardiology Fellows
UCSF Medicine 110; Family and Community Medicine Lecture Series
UCSF Medicine 132a; Introduction to Clinical Medicine
UCSF Medicine 140.22; Pathophysiology of Disease-Clinical Pharmacology and Therapeutics
UCSF Medicine 140.35; Cardiology Consultation
UCSF Medicine 140; Medicine Ward Service-Cardiology
UCSF Dept. of Medicine Core Curriculum for Primary Care Housestaff
UCSF Dept. of Medicine Core Curriculum for Medical Housestaff
UCSF Medicine 111; Mechanisms of Disease
UNM Cardiology Journal Club
UNM Cardiology Fellows Conference Series
UNM Cardiology Graphics Conference Series
UNM Internal Medicine Residents Core Curriculum Series
UNM Continuity Clinic Phase II Medical Student Preceptorships
Lovelace Clinic Foundation Medical Education Division Faculty Member
Menaul High School Preceptorship Program
Attending, Medicine Team D, Frankford-Torresdale Hospital, Jefferson Medical System
Philadelphia College of Osteopathic Medicine, Medicine Preceptorships
AEMC Cardiology Fellowship Conference Curriculum, Director
AEMC Internal Medicine Residents Morning Report
AEMC Internal Medicine Core Curriculum Series
Experience Day, Germantown Friends School 9th Grade
AEMC Internal Medicine Journal Club
Recognition
Lovelace Clinic Foundation Excellence in Education Award 2002
Frankford Hospitals, Jefferson Health System, Dedication to Teaching Award 2006
Philadelphia College of Osteopathic Medicine, Outstanding Contribution Award 2006/2007
Einstein Leadership Development Program 2009-2010
University and Public Service, Committees
Pharmacy and Therapeutics Committee, San Francisco Department of Public Health 1995
San Francisco Injury Center Advisory Committee, 1996, 1997
SFGH Multidisciplinary Procedures Task Force 1997
SFGH Formulary Review Subcommittee 1997
Guest Speaker, Cardiac Health Symposium, California Pacific Medical Center, S.F., 1998
Member, Continuing Medical Education Advisory Committee, Lovelace Health Systems, 2000
Member, Physician Information Systems Advisory Group, Lovelace Health Systems, 2000
Speaker, Lovelace Health Systems Community Seminar, The Ins and Outs of Heart Disease, 2000
Member, Billing Steering Committee, Lovelace Health Systems, 2000
Member, Pharmacy and Therapeutics Committee, Lovelace Health Systems, 2000
Board Member, Medical Advisory Board, American Heart Association, Pacific Mountain Affiliate, 2001
Co-Director, New Mexico Hypertension Journal Club, 1999-2001
Pharmacy and Therapeutics Committee, Lovelace Health Systems 2000-2002
Panel Member, “Hard Facts About Women and Heart Disease”, Lovelace Women’s Health Services and
the Spirit of Women “Day for You”, 2002
3
Figueredo, V.M.
Author, “Lower cholesterol levels urged for older adults”, Mature Life in New Mexico Section,
Albuquerque Journal, June 2002
Author, “Hormone Replacement Therapy and Heart Disease”, Mature Life in New Mexico Section,
Albuquerque Journal, December 2002
Board of Governors, Lovelace Clinic Foundation 2003
Panel Member, “Pour Your Heart into it: Preventing and Managing Heart Disease From the Corporate to
the Hospital Setting”, presented by Lovelace Clinic Foundation, April 2003
Member, Disease Management Program, Lovelace Health Systems, 2003
Member, Physician Planning Council, Lovelace Sandia Health Systems, 2004
Member, Lovelace Medical Center Community Advisory Board, 2005
Albert Einstein Medical Center Curriculum Committee, 2007-2008
Albert Einstein Medical Center Clinical Competency Committee, 2007-2008
Judge, Albert Einstein Medical Center Intern Research Competition, 2007
Albert Einstein Medical Center Academic Issues Committee, 2007-2008
Albert Einstein Medical Center Faculty Advisor for Housestaff, 2007-2008
Albert Einstein Medical Center Housestaff Selection Committee, 2007-2008
Chair, Education/Quality of Care/Guidelines Committee, Pennsylvania Chapter, American College of
Cardiology, 2007-2008
Executive Committee, Pennsylvania Chapter, American College of Cardiology, 2007-2008
Albert Einstein Medical Center Cardiology Strategic Planning Committee, 2007-2008
Albert Einstein Medical Center Cardiology Steering Committee, 2007-2010
Chair, CCA Planning Committee, Pennsylvania Chapter, American College of Cardiology, 2008-2009
Chapter Meeting Planning Committee, PA Chapter, American College of Cardiology, 2008-2009
Nominating Committee, PA Chapter, American College of Cardiology, 2008-2009
Chair, Education Committee, Pennsylvania Chapter, American College of Cardiology, 2009-2010
Albert Einstein Medical Center Cardiology IS Steering Committee, 2009-2010
Jefferson Medical College Curriculum Committee Electives Working Group 2010
Editor, Pennsylvania Chapter American College of Cardiology Newsletter, 2010
Invited Lectures and Visiting Professorships
Dept. of Cardiology Seminar Series, San Francisco General Hospital, CA, 1994
Cardiology Grand Rounds, University of California, SF, CA, 1995
Medical Grand Rounds, San Francisco General Hospital, CA, 1995
Cardiology Grand Rounds, San Francisco VA Medical Center, SF, CA, 1995
Medical Grand Rounds, San Francisco VA Medical Center, SF, CA, 1996
Medical Grand Rounds, Summit Hospital, Oakland, CA, 1997
Medical Grand Rounds, Santa Theresa Community Hospital, 1997
Medical Grand Rounds, Community Hospital of Monterey Peninsula, 04/1997
Horizons Lecture Series for UCSF Medical Students, 1997
Medical Grand Rounds, Community Hospital of Monterey Peninsula, 07/1997
NIAAA/RSA Scientific Meeting with Wine Institute, San Francisco, CA, 1997
Departments of Physiology and Biophysics Seminar, Univ. of Illinois, Chicago, IL 1997
Cardiology Grand Rounds, RUSH-Presbyterian Medical Center, Chicago, IL, 1997
Cardiology Grand Rounds, Loyola University Medical Center, Chicago, IL, 1997
Medical Grand Rounds, Michael Reese Medical Center, Chicago, IL, 1997
4
Figueredo, V.M.
Nephrology Grand Rounds, Christ Hospital, Oak Lawn, IL, 1998
General Medicine Grand Rounds, Holy Cross Hospital, Chicago, IL, 1998
Medical Grand Rounds, Dameron Hospital Stockton, CA, 1998
Medical Grand Rounds, Memorial Hospital of Sheridan County, WO, 1998
Medical Grand Rounds, Univ. of New Mexico Health Sciences Center, Albuquerque, NM, 1998
Medical Grand Rounds, Washington Hospital, Freemont, CA, 1998
Medical Grand Rounds, Gila Medical Center, Silver City, NM, 1999
Medical Grand Rounds, Lakewood Regional Medical Center, Lakewood, CA, 1999
Medical Grand Rounds, Eastern New Mexico Medical Center, Roswell, NM, 1999
Cardiology Mentoring Program, Ingalls Hospital, Harvey, IL, 1999
Medical Grand Rounds, Lamb Healthcare Center, Littlefield, TX, 1999
Internal Medicine Resident Teaching Conf, Texas Tech Health Sciences Center, Lubbock, TX, 1999
Continuing Medical Education Program, Northern Navajo Medical Center, Shiprock, NM, 1999
Medical Grand Rounds, Lankenau Hospital, Lankenau, PA, 1999
Pottawatomie County Medical Society Annual Meeting, Shawnee, OK, 1999
Medical Grand Rounds, Mendocino Coast District Hospital, Ft. Bragg, CA, 1999
Medical Grand Rounds, San Juan Regional Medical Center, Farmington, NM, 1999
Medical Grand Rounds, Maricopa Medical Center, Phoenix, AZ, 1999
Grand Rounds, Lankenau Hospital, Lankenau, PA, 2000
Medical Grand Rounds, Gila Medical Center, Silver City, NM, 2000
Annual Faculty Meeting, Holy Cross Medical Group, Ft. Lauderdale, FL, 2000
Medical Grand Rounds, Kirtland 377th Medical Group, Albuquerque, NM, 2000
Medical Grand Rounds, Mt. Diablo Medical Center, Concord, CA, 2001
Medical Grand Rounds, St. Mary's Hospital, Grand Junction, CO, 2001
Medical Grand Rounds, John Muir/Mt. Diablo Medical Center, Walnut Creek, CA, 2001
Medical Grand Rounds, Kirtland 377th Medical Group, Albuquerque, NM, 2001
Medical Grand Rounds, Granada Hills Community Hospital, Granada Hills, CA, 2001
Medical Grand Rounds, Univ. of New Mexico Health Sciences Center, Albuquerque, NM, 2001
Journal Center Best Practice Grand Rounds, Lovelace Clinic, Albuquerque, NM, 2001
Speaker, Lovelace Health Systems Clinical Update CME Program, Albuquerque, NM, 2002
Guest Speaker, New Mexico Pharmaceutical Association Annual Meeting, Albuquerque, NM 2002
Speaker, Lovelace Clinic Foundation Regional CME Program, Albuquerque, NM 2002
Medical Grand Rounds, Los Alamos Medical Center, NM, 2003
Medical Grand Rounds, Albuquerque Veterans Administration Medical Center, NM, 2003
Family Medicine Grand Rounds, Univ. of New Mexico Health Sciences Center, Albuquerque, 2003
Speaker, Lovelace Health Systems Primary Care Symposium, Albuquerque, NM, 2003
Cardiology Grand Rounds, Albert Einstein Medical Center, Philadelphia, PA, 2005
Cardiology Grand Rounds, Paoli Hospital, Paoli, PA, 2005
Frankford Hospitals Grand Rounds, Philadelphia, PA 2006
Medical Grand Rounds, Albert Einstein Medical Center, Philadelphia, PA, 2006
Medical Grand Rounds, Albert Einstein Medical Center, Philadelphia, PA, 2008
Psychiatry Grand Rounds, Albert Einstein Medical Center, Philadelphia, PA, 2008
Cardiology Grand Round, Temple University Medical Center, Philadelphia, PA 2008
Cardiology Grand Round, Lankenau Medical Center, Philadelphia, PA 2009
5
Figueredo, V.M.
Meeting Faculty Member
Annual Advances in Heart Disease, American College of Cardiology, SF, CA, 1994
27th Int’l Medical Advisory Group Conf. on Alcohol Research, Vancouver, Canada, 1998
15th Winter Medical Symposium, NM Osteopathic Medical Assoc., Taos, NM, 1999
Update in Primary Care, NM Hispanic Medical Assoc., Albuquerque, NM, 1999
Texas Pharmacy Association Continuing Education Meeting, El Paso, TX 2000
21st Annual Southwest Association of Hispanic American Physicians Medical Education Congress, El
Paso, TX 2000
Second Annual New & Current Therapies in Heart and Vascular Care, ABQ, NM, 2001
Third Annual New & Current Therapies in Heart and Vascular Care, ABQ, NM, 2002
Fourth Annual New & Current Therapies in Heart and Vascular Care, ABQ, NM, 2003
New Mexico Primary Care Symposium, Santa Fe, NM, 2003
New Mexico Osteopathic Medical Assoc., 23rd Annual Balloon Fiesta Medical Symposium,
Albuquerque, NM, 2003
Fifth Annual New & Current Therapies in Heart and Vascular Care, ABQ, NM, 2004
Advanced Preceptorship in the Management of Anticoagulation Therapy and Clinical Thrombosis,
Fifth World Congress on Stress, London, England 2004
Sixth Annual New & Current Therapies in Heart and Vascular Care, ABQ, NM, 2005
Advanced Preceptorship in the Management of Anticoagulation Therapy and Clinical Thrombosis,
Sixth World Congress on Stress, Vienna, Austria, 2007
Pennsylvania Academy of Family Physicians, Clinical Education Series, Skytop, PA 2009
Pennsylvania ACC Cardiac Care Associates Educational Conference, Hershey, PA May 1, 2009
American College of Cardiology Pennsylvania Chapter 2009 Annual Scientific Meeting, Skytop, PA,
October 2-4, 2009
EuroEcho, European Society of Cardiology, Madrid, Spain, December 9-12, 2009
Pennsylvania ACC Cardiac Care Associates Educational Conference, Hershey, PA April 30, 2010
Pennsylvania ACC Cardiac Care Associates Educational Conference, Pittsburgh, PA May 14, 2010
Grant Reviewer
Biomedical Research Review Subcommittee, National Institute on Alcohol Abuse and Alcoholism,
National Institutes of Health, 2/99 & 11/99.
Abstract Reviewer
American College of Cardiology’s 59th Annual Scientific Session, 2010.
Coordinating Editor
Practical Reviews Cardiology, Oakstone Medical Publishing 2009-present.
Manuscript Reviewer
Alcoholism Clinical and Experimental Research
American Journal of Medicine
American Journal of Physiology
Annals of Internal Medicine
6
Figueredo, V.M.
Basic Research in Cardiology
Cardiovascular Drugs and Therapeutics
Echocardiography
International Journal of Cardiology
Lancet
Journal of the American College of Cardiology
Journal of Molecular and Cellular Cardiology
Stress and Health: Journal of the International Society for the Investigation of Stress
7
Figueredo, V.M.
BIBLIOGRAPHY
Publications
1. Figueredo VM and Neu HC: Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas
isolates from patients with cystic fibrosis. J Antimicrob Chemo 1988;22:41-50.
2. Chin NX, Figueredo VM, Novelli A, and Neu HC: In vitro activity of temafloxacin, a new
difluoroquinolone antimicrobial agent. Eur J Clin Microbiol 1988;7:58-63.
3. Figueredo VM, Dresdner KP, Wolney AC, and Keller AM: Postischaemic reperfusion injury in the
isolated rat heart: effect of ruthenium red. Cardiovasc Res 1991;25:337-342.
4. Brandes R, Figueredo VM, Camacho SA, Massie BM, and Weiner MW: Suppression of motion
artifacts in fluorescence spectroscopy of perfused hearts. Am J Physiol 1992;263(Heart Circ
Physiol):H972-H980.
5. Figueredo VM, Brandes R, Weiner MW, Massie BM, and Camacho SA: Cardiac contractile
dysfunction during mild coronary flow reductions is due to an altered calcium-pressure relationship in
rat hearts. J Clin Invest 1992;90:1794-1802.
6. Camacho SA, Figueredo VM, Brandes R, and Weiner MW: Ca2+-dependent fluorescence transients
and phosphate metabolism during low-flow ischemia in perfused hearts. Am J Physiol 1993; 268(Heart
Circ Physiol): H114-H122.
7. Brandes R, Figueredo VM, Camacho SA, Baker AJ, and Weiner MW: I. Quantitation of cytosolic
[Ca2+] in whole perfused rat hearts using Indo-1 fluorometry. Biophys J 1993;65:1973-1982.
8. Brandes R, Figueredo VM, Camacho SA, Baker AJ, and Weiner MW: II. Investigation of factors
affecting fluorometric quantitation of cytosolic [Ca2+] in perfused hearts. Biophys J 1993;65:19831993.
9. Figueredo VM, Brandes R, Weiner MW, Massie BM, and Camacho SA: Endocardial versus
epicardial differences of intracellular free calcium under normal and ischemic conditions in perfused rat
hearts. Circ Res 1993; 72:1082-1090.
10. Brandes R, Figueredo VM, Camacho SA, and Weiner MW: Compensation for changes in tissue
light absorption in fluoremetry of hypoxic perfused rat hearts. Am J Physiol 1994;266:H2554-H2567.
11. Camacho SA, Brandes R, Figueredo VM, and Weiner MW: Ca2+ transient decline and myocardial
relaxation are slowed during low-flow ischemia in rat hearts. J Clin Invest 1994;93:951-957.
12. Schreur JH, Figueredo VM, Shames DM, and Camacho SA: Cytosolic [Ca2+] transients from
whole hearts using indo-1 AM: correction for non-cytosolic fluorescence. Biophys J 1996;70:25712580.
13. Miyamae M, Camacho SA, Weiner MW, and Figueredo VM: Attenuation of postischemic
reperfusion injury is related to prevention of mitochondrial Ca2+, not cytosolic Ca2+, overload in rat
heart. Am J Physiol 1996;271:H2145-H2153.
14. Miyamae M, Camacho SA, Weiner MW, Diamond I, and Figueredo VM: Regular alcohol
consumption mimics cardiac preconditioning by protecting against ischemia-reperfusion injury. Proc
Nat Acad Sci USA 1997;94:3235-3239.
15. Miyamae M, Camacho SA, Rooney WD, Modin G, Chang KC, Weiner MW, and Figueredo VM:
Inorganic phosphate and coronary perfusion pressure contribute equally to contractile dysfunction
during graded ischemia in rat heart. Am J Physiol 1997; 42(2):H566-H582.
16. Chang KC, Figueredo VM, Schreur JHM, Kariya K, Weiner MW, Simpson PC, Camacho SA:
Thyroid hormone reverses slowing of myocardial relaxation induced by pressure-overload hypertrophy:
relationship to changes of Ca2+ handling and expression of sarcoplasmic reticulum Ca2+-ATPase and
myosin heavy chain in rats. J Clin Invest 1997;100(7):1742-1749.
17. Figueredo VM, Chang KC, Baker AJ, Camacho SA: Chronic alcohol - induced changes of cardiac
contractility are not due to changes in the cytosolic Ca2+ transient. Am J Physiol 1998;275(Heart Circ
Physiol 44):H122-H130.
8
Figueredo, V.M.
18. Miyamae M, Camacho SA, Baker AJ, Zhong HZ, Weiner MW, Diamond I, and Figueredo VM:
Alcohol consumption reduces ischemia-reperfusion injury by species-specific signaling in guinea pig
and rat. Am J Physiol 1998;275(Heart Circ Physiol 44):H50-H56.
19. Baker AJ, Figueredo VM, Keung EC, and Camacho SA: Ca2+ regulates the kinetics of tension
development in intact cardiac muscle. Am J Physiol 1998;275(3 Pt 2):H744-750.
20. Ho RT, Nanevicz T, Yee R, Figueredo VM. Benzocaine induced methemoglobinemia – two case
reports related to transesophageal echocardiography medication. Cardiovasc Drug Therapy
1998;12(3):311-312.
21. Tian R, Halow JH, Meyer M, Dillman WH, Figueredo VM, Ingwall JS, Camacho SA:
Thermodynamic limitation for Ca2+ handling contributes to decreased contractile reserve in rat hearts.
Am J Physiol 1998;275(6 Pt 2):H2064-2071.
22. Miyamae M, Rodriguez MM, Camacho SA, Diamond I, Mochly-Rosen D, Figueredo VM:
Activation of epsilon protein kinase C correlates with a cardioprotective effect of moderate ethanol
consumption. Proc Nat Acad Sci 1998;95:8262-8267.
23. Rozycki GS, Feliciano DV, Oschner MG, Knudson MM, Hoyt DB, Davis F, Hammerman D,
Figueredo V, Harviel JD, Han DC, Schmidt JA: The role of ultrasound in patients with possible
penetrating cardiac wounds: A prospective multicenter study. J Trauma 1999;46(4):543-551.
24. Figueredo VM, Diamond I, Zhou H-Z, Camacho SA: Chronic dipyridamole therapy produces
sustained protection against cardiac ischemia-reperfusion injury. Am J Physiol 1999:277(Heart Circ
Physiol 46):H2091-H2097.
25. Halow JH, Figueredo VM, Shames DM, Camacho SA, Baker AJ: Role of slowed Ca2+ transient
decline in slowed relaxation during myocardial ischemia. J Mol Cell Cardiol 1999 Sep;31(9):1739-48.
26. Wang L, Cherednichenko G, Hernandez L, Halow J, Camacho SA, Figueredo V, Schaefer S.
Preconditioning limits mitochondrial Ca(2+) during ischemia in rat hearts: role of K(ATP) channels. Am
J Physiol Heart Circ Physiol. 2001 May;280(5):H2321-H2328.
27. Pharr JR, West MB, Kusumoto FM, Figueredo VM: Prominent crista terminalis appearing as a right
atrial mass on transthoracic echocardiogram. J Am Soc Echocardiogr 2002;15:753-755.
28. Pharr JR, Figueredo VM: Lipomatous hypertrophy of the atrial septum and prominent crista
terminalis appearing as a right atrial mass. Euro J Echocardiogr 2002;3(2):159-161.
29. Miyamae M, Fujiwara H, Tanaka M, Yokota R, Takemura G, Itoh S, Domae N, Figueredo VM:
Oxygen radicals mediate metabolic and ultrastructural protection of preconditioning in vivo in pig
hearts. Exp Clin Cardiol 2003;7(4):173-178.
30. Miyamae M, Domae N, Zhou H-Z, Sugioka S, Diamond I, Figueredo VM: Phospholipase C
Activation is required for cardioprotection by ethanol consumption. Exp Clin Cardiol 2003;8(4):184188.
31. Jaffe W and Figueredo VM: An example of Lambl’s excrescences by transesophageal
echocardiogram: A commonly misinterpreted lesion. Echocardiography 2007;24(10):1086-1089.
32. Kaneda K, Miyamae M, Sugioka S, Okusa C, Inamura Y, Domae N, Kotani J, Figueredo VM:
Sevoflurane enhances ethanol-induced cardiac preconditioning through modulation of nitric oxide
synthase, protein kinase C and mitochondrial KATP channels in Guinea pig hearts. Anesth Analg 2008;
106:9-16.
33. Maraj S, Pressman G, Figueredo VM: Primary cardiac tumors. Int J Cardiol. 2009;133(2):152-6.
34. Dhar D, Pressman G, Subramanian S, Kaul S, Gollamudi S, Bloom E, and Figueredo VM:
Natriuetric peptides and their role in heart failure in the setting of chronic renal disease: a review of
current evidence. Postgrad Med J 2009:85(1004):299-302.
35. Mehta S, Parameswaran AC, Greenspan, A. Figueredo VM. Hypercalcemia due to rhabdomyolysis
mimicking Brugada syndrome. Pacing Clin Electrophysiol 2009;32(11):e14-5.
9
Figueredo, V.M.
36. Okusa C, Miyamae M, Sugioka S, Kaneda K, Inamura Y, Onishi A, Domae N, Kotani J, Figueredo
VM. Acute memory phase of sevoflurane preconditioning is associated with sustained translocation of
PKC-α and ε, but not δ, in isolated guinea pig hearts. Eur J Anaesthesiol 2009;26(7):582-8.
37. Figueredo VM and Pressman GS. Development of an intra-operative left atrial thrombus? J Am Coll
Cardiol 2009 Aug 4;54(6):e1.
38. Chunhamaneewat N, Maraj S, Borate U, Figueredo VM. A 28-year old woman with headache,
blurred vision and splinter hemorrhages Am J Med Sci 2009;338(6):493.
39. Pressman GS, Crudu V, Parameswaran-Chandrika A, Romero-Corral A, Purushottam B, Figueredo
VM. Can total cardiac calcium predict the coronary calcium score? Int J Cardiol. 2009 Jul 15. [Epub
ahead of print].
40. Figueredo VM and Gupta S. Embolic complication of tako-tsubo cardiomyopathy. QJM
2009;102(11):820-2.
41. Figueredo VM. The time has come for physicians to take notice: the impact of psycosocial stressors
on the heart. Am J Med. 2009;122(8):704-12.
42. Inamura Y, Miyamae M, Sugioka S, Kaneda K, Okusa C, Onishi A, Domae N, Kotani J, Figueredo
VM. Aprotinin abolishes sevoflurane postconditioning by inhibiting nitric oxide production and
phosphorylation of protein kinase C-δ and glycogen synthase kinase 3β. Anesthesiology
2009;111(5):1036-43.
43. George A and Figueredo VM. Alcohol and arrhythmias: a comprehensive review. J Cardiovasc
Med (Hagerstown). 2010 Apr;11(4):221-8.
44. Maraj S, Figueredo VM, Lynn Morris D. Cocaine and the heart. Clin Cardiol. 2010 May;33(5):264269.
45. Gupta S, Pressman GS, Morris DL, and Figueredo VM. Distribution of left ventricular ejection
fraction in angina patients with severe coronary artery disease not amenable to revascularization.
Coronary Artery Disease 2010 Aug;21(5):278-80.
46. George A, Arumugham PS, Figueredo VM. aVR – the forgotten lead. Exp Clin Cardiol 2010
Summer;15(2):e36-44.
47. Moinuddin M, Figueredo VM, Amanullah A. Infiltrative Diseases of the Heart: A Systematic
Review. Reviews in Cardiovascular Medicine. 2010;in press.
48. Makkuni P, Kotler M, Figueredo VM. Diverticular and aneurysmal structures of the left ventricle in
adults. Texas Heart Institute Journal. 2010;in press.
45. Gupta S, Pressman GS, and Figueredo VM. Incidence of, Predictors for, and Mortality Associated
with Malignant Ventricular Arrhythmias in Non-ST Elevation Myocardial Infarction Patients. Coronary
Artery Disease 2010 Sep 24. [Epub ahead of print].
46. Figueredo VM, Pressman GS, Romero-Corral A, Murdock E, Holderbach P, Morris DL.
Improvement in Left Ventricular Systolic and Diastolic Performance During Ranolazine Treatment in
Patients With Stable Angina. J Cardiovasc Pharmacol Ther 2010 Oct 5. [Epub ahead of print].
10
Figueredo, V.M.
Invited Reviews and Book Chapters:
1. Figueredo VM and Weiner MW: Magnetic resonance of the heart. Chapter in Clinical Applications
of Magnetic Resonance Spectroscopy, S. Narusa, ed.; Igaku-Shoin LTD, Tokyo; 1991;117-128.
2. Figueredo VM and Camacho SA: Basic mechanisms of myocardial dysfunction: cellular
pathophysiology of heart failure. Current Opinion Cardiol 1993; 8:369-375.
3. Amidon TM, Figueredo VM, and Wolfe CL: Thrombolytic therapy in acute myocardial infarction.
Hospital Formulary 1993; 28:558-572.
pathophysiology of heart failure. Current Opinion Cardiol 1994;9:272-279.
5. Figueredo VM and Cheitlin M: Risk stratification. Chapter in Management of Acute Myocardial
Infarction , Braunwald E and Julian DG, eds., WB Saunders LTD, London, 1994:361-391.
6. Figueredo VM, Amidon TM, and Wolfe CL: Thrombolysis after acute myocardial infarction. Who
should be added to inclusion criteria? Postgrad Med 1994;96(8):30-40.
7. Figueredo VM, Amidon TM, and Wolfe CL: Adjuvant therapy with thrombolysis in acute
myocardial infarction: antiplatelet agents, antithrombotic agents, and the role of angioplasty. Postgrad
Med 1994;96(8):45-54.
pathophysiology of heart failure. Current Opinion Cardiol 1995;10(3):246-252.
9. Pharmacy and Therapeutics Committee, San Francisco Department of Public Health: Guidelines for
cost-effective treatment of hypertension in adults. Pharmacy and Therapeutics Forum 1996;44(4,5):1-5.
10. Figueredo VM and Goldschlager N: Ventricular arrhythmias and sudden death in patients with
myocardial dysfunction due to myocardial infarction and dilated cardiomyopathy: a clinical perspective.
Chapter in Interventional Electrophysiology, Saksena S and Luderitz B, eds., Futura Publishing Co.,
Inc., New York, 1996;165-184.
11. Figueredo VM: Risk stratification after acute myocardial infarction. Postgrad Med 1996;99(4):207214.
12. Figueredo VM: Alcohol Effects on the Cardiovascular System. Section in the Ninth Special Report
to the U.S. Congress on Alcohol and Health from the Secretary of Health and Human Services, U.S.
Department of Health and Human Services, June 1997.
13. Figueredo VM and Mochly-Rosen D: Ethanol and signal transduction in the myocardium:
implications for the detrimental and beneficial effects. Chapter in Alcohol and the Cardiovascular
System, Zakhari S and Wassef M, eds., CSR, Inc., Washington, DC, 1996;263-278.
14. Figueredo VM: The effects of alcohol on the heart: detrimental or beneficial? Postgrad Med
1997;101(2):165-176.
15. Camacho SA and Figueredo VM: Alcohol and the cardiovascular system. Chapter in Cardiology
Loose Leaf, Parmley WW and Chatterjee K, eds., Lippincott-Raven Publishers, Philadelphia, 1997;3:121.
16. Figueredo VM: Alcohol Effects on the Cardiovascular System. Section in the Tenth Special Report
to the U.S. Congress on Alcohol and Health from the Secretary of Health and Human Services, U.S.
Department of Health and Human Services, June 2000.
17. Bishop T and Figueredo VM: Hypertension therapy: Attacking the renin-angiotensin system.
Western J Med 2001;175(2):119-124.
18. Miyamae M, Sugioka S, Figueredo VM: Additive cardioprotection by ethanol and sevoflurane: Are
sarcolenmal KATP channels also involved? Response to Letter to the Editor. Anesth Analg
2008;106(6):1926-1927.
19. Miyamae M, Kaneda K, Domae N, Figueredo VM. Cardioprotection by regular ethanol
consumption: potential mechanisms and clinical application. Curr Drug Abuse Rev. 2010 Mar;3(1):3948.
11
Figueredo, V.M.
Abstracts (those which have appeared in manuscript form are not included):
1. Baker AJ, Keung EC, Camacho SA, Figueredo VM, Weiner MW: Slowed myocardial relaxation
with high preload is not due to slowed decline of activation. Biophys J 1996; 70:A40.
2. Miyamae M, Rodriguez M, Chang KC, Camacho SA, Mochly-Rosen D, Figueredo VM:
Immunolocalization of activated epsilon protein kinase C in isolated adult cardiomyocytes. J Am Coll
Cardiol 1997;29(2):345A.
3. Rodriguez MM, Miyamae M, Camacho SA, Diamond I, Mochly-Rosen D, Figueredo VM: Protein
kinase C translocation with chronic ethanol exposure: potential mechanism for a chronic
cardioprotective effect against reperfusion injury. J Am Coll Cardiol 1998;31(2):448A.
4. Hutchison SJ, Sudhir K, Chou TM, Chatterjee K, Figueredo VM: Nitric oxide-mediated vasodilation
(tolerance) to hypertensive effects of ethanol. J Am Coll Cardiol 1998;31(2):262A.
5. Gray MO, Zhou HZ, Dulbecco FL, Figueredo VM, Karliner JS: Mechanisms of cardiac
preconditioning in a mouse model of moderate ethanol consumption. FASEB 1999.
6. Beaton SJ, Walker SG, Jaseph M, Boyson C, Brake AD, Dole EJ, Gleeson JM, Gunter MJ, Figueredo
VM. Implementation and Evaluation of a Lipid Telemanagement Program. Journal of Managed Care
Pharmacy 2002; 8(2):110.
7. Sugioka S, Miyamae M, Domae N, Figueredo VM, Kotani J. Blockade of p38 mitogen activated
protein kinase before and during ischemia does not abolish sevoflurane-induced cardiac preconditioning
in Guinea Pigs. Annual Meeting Program of American Society of Anesthesiologists. 2004:339:A-708.
8. Figueredo VM. Is Emotional Distress a Cause or Consequence of Chronic Illness? Fifth World
Congress on Stress. London, England. 2004.
9. Kaneda K, Miyamae M, Sugioka S, Okusa C, Domae N, Figueredo VM, Kotani J. Sevoflurane
Enhances Ethanol-Induced Cardiac Preconditioning Through Mitochondrial KATP channels and Protein
Kinase C Activation in Guinea Pig Hearts. Annual Meeting of International Anesthesia Research
Society. 2006.
10. Sugioka S, Miyamae M, Okusa C, Kaneda K, Domae N, Figueredo VM, Kotani J. Sevoflurane
Preconditioning Does not Diminish Phosphorylation of p38 MAPK and MAPKAPK 2 During Sustained
Ischemia. Annual Meeting of American Society of Anesthesiologists. 2006.
11. Scales R, Maes JD, Malott T, Figueredo VM, Ketchens V, Ferguson K, Rollinson D. Lovelace
Cardiac Rehabilitation: A guideline to quality programming. Journal of Exercise Physiology (online)
2006;abstract 16;9:2.
12. Kaneda K, Miyamae M, Sugioka S, Okusa C, Inamura Y, Domae N, Figueredo VM, Kotani J.
Preconditioning-Like Cardioprotection by Regular Ethanol Consumption Lasts at Least 7 Days After
Abstention and is Associated With eNOS Upregulation. J Am Coll Cardiol 2007;49(9A):235A.
13. Okusa C, Miyamae M, Sugiok S, Kaneda K, Domae N, Kotani J, Figueredo VM. Anesthetic
Preconditioning by 2% Sevoflurane is Lost within 1 hr After a Brief Exposure in Isolated Guinea Pig
Hearts. Annual Meeting of International Anesthesia Research Society. 2007.
14. Figueredo VM. The Time Has Come For Physicians to Take Notice: The Impact of Emotional
Stress on the Heart. Sixth World Congress on Stress. Vienna, Austria. 2007.
15. Harralson T; McLaughlin M, Walker R, Polansky M, Figueredo VM. Psychosocial Characteristics
and Symptomatology of Patients Presenting to the Hospital with Non-Cardiac Versus Cardiac Chest
Pain. Society of Behavioral Medicine's 29th Annual Meeting and Scientific Sessions. March, 2008.
16. Kaneda K, Miyamae M, Sugioka S, Okusa C, Inamura Y, Onishi A, Domae N, Figueredo VM,
Kotani J. Persistent Cardioprotection by Regular Ethanol Consumption After Abstention Depends on
eNOS but not iNOS Activity After Reperfusion. Circulation. 2008;118:S498.
12
Figueredo, V.M.
17. Gupta S and Figueredo VM. Ventricular Arrhythmias in patients with Non-ST Elevation
Myocardial Infarction (NSTEMI): Incidence, Predictors and Mortality. J Am Coll Cardiol 2009;53(10
Suppl A):A316.
18. Purushottam B, Parameswaran AC, Figueredo VM. Prevalence of Dyssynchrony in Obese Subjects
With No Known Cardiac Disease Using Velocity Vector Imaging. Circulation 2009;120:S745.
19. Gupta S and Figueredo VM. Effects of Renal Function on Outcomes of Patients with Non-ST
Elevation Myocardial Infarction (NSTEMI) Treated with Early Invasive Strategy. Society of Critical
Care Medicine's 39th Critical Care Congress. January 2010.
20. Miyamae M, Domae N, Vincent M. Figueredo VM. Protein kinase activation and cardioprotection
by regular ethanol consumption and volatile anesthetics. (Oral presentation) BIT Life Science’ 3rd
Annual Protein and Peptide Conference, Beijing, China, March 22, 2010.
21. Chebrolu L, Kao CK, Cardona R, Braverman D, Kim J, Pomerantz SC, Figueredo VM. Comparison
of enhanced external counter pulsation outcomes in refractory angina patients with and without atrial
fibrillation. National American College of Physicians Meeting, Toronto, Canada, 2010.
22. Okusa C, Miyamae M, Domae N, Figueredo VM, Kotani J. Combined pharmaceutical cardiac
preconditioning with dipyridamole and sevoflurane or a NO donor. Annual Meeting of American
Society of Anesthesiologists. 2010.
23. Arishiro K, Miyamae M, Momota Y, Okusa C, Kotani K, Domae N, Figueredo VM. Remote
preconditioning by carotid artery occlusion limits myocardial infarct size: role of MAPK. Annual
Meeting of American Society of Anesthesiologists. 2010.
24. Kaneda K, Miyamae M, Sugioka S, Okusa C, Inamura Y, Onishi A, Shiomi M, Domae N,
Figueredo VM, Kotani J. Cardioprotection by regular ethanol consumption is mediated through the
bradykinin B2 receptor through increased nitric oxide production. Circulation 2010: in press.
13
Figueredo, V.M.
Newspaper Articles
1. Figueredo VM. Lower cholesterol levels urged for older adults. Albuquerque Journal (Living
Section). June 16, 2002.
2. Figueredo VM. Doctor Offers More on Hormones and Heart Disease. Albuquerque Journal (Mature
Life). February 2003.
3. Scales R and Figueredo VM. Heart-Related Diseases are Occurring at Earlier Ages. Albuquerque
Journal (Mature Life). March 2004.
14
Figueredo, V.M.
CLINICAL TRIALS
1. Valsartan in Acute Myocardial Infarction (VALIANT). Protocol # CVAL489 0108. 1999. Principal
Investigator.
2. A Phase II, Randomized, Open-Label, Crossover, Multicenter, Multidose Study of the Safety,
Pharmacokinetics and Pharmacodynamics in DMP 754 (Roxifiban) in Combination with Aspirin in
Patients with Coronary Artery Disease. Protocol # DMP 754-017. 1999. Principal Investigator.
3. A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and
Tolerability of early Treatment with Simvastatin 40 mg Daily for 30 Days, Followed by Simvastatin 80
mg Daily Thereafter in Tirofiban-Treated Acute Coronary Syndrome Patients Who Have Been
Randomized to Receive Enoxaparin or Unfractionated Heparin in Conjunction with Aspirin. Protocol #
MK-0733 US A2Z. 2000. Co-Investigator.
4. Omipatrilat in Persons with Enhanced Risk of Atherosclerotic Events (OPERA). Protocol CV137056. 2000. Principal Investigator.
5. Omipatrilat Versus Enalapril Randomized Trial of utility in Reducing Events (OVERTURE). Protocol
CV137-068. 2000. Principal Investigator.
6. A Multicenter Prospective, Randomized, Double-Blinded, Parallel Group Study Comparing the
Effects of Lotrel (5/20mg) to Amlodipine (5mg) and Benazepril (20mg) on Systolic Blood Pressure and
Pulse Pressure in Patients with Systolic Hypertension (SELECT). Protocol CCIB002FUS08. 2002.
Principal Investigator.
7. A Multicenter, Double Blind, Placebo Controlled Trial to Evaluate the Effect of Extended Release
Metoprolol Succinate (Toprol XL) on Cardiac Remodeling in Asymptomatic Heart Failure Patients
(NYHA Class I) with Left Ventricular Dysfunction (REVERT). Protocol 276 Astra Zeneca. 2003.
8. A Multicenter Prospective, Randomized, Double-Blinded, Parallel Group, 6-Week Study to Evaluate
the Efficacy and Safety of Ezetimibe 10 mg/day When Added to Ongoing Therapy with a Statin Versus
Statin Therapy Alone, in Patients with Hypercholesterolemia Who Have Not Reached National
Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Target LDL-Cholesterol
Level. EASE Trial: Ezetimibe Add-On to Statin for Effectiveness Trial. ProtocolMK-0653. 2003.
9. A Multicenter, randomized, double-blind, placebo-controlled, parallel group study comparing
aliskiren 150 mg, 300 mg, and 600 mg to placebo and irbesartan 150 mg in patients with mild-tomoderate essential hypertension. Protocol CSPP100A2201. 2003. Principal Investigator.
10. VERITAS-2: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to
Assess the Efficiency, Safety, and Tolerability of Tezosentan in Patients with Acute Heart Failure.
Protocol AC-051-307. 2003. Principal Investigator.
15
Figueredo, V.M.
11. A 6-week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of
Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolemia in Hispanic Subjects. Protocol
No. 4522US0007. 2005. Principal Investigator.
12. A 12-Week, Randomized, Open-Label, 3-Arm, Parallel Group, Multicenter, Phase IIIb Study
Comparing the Efficacy and Safety of Rosuvastatin 20 mg and 40 mg with that of Atorvastatin 80 mg in
Subjects with Acute Coronary Syndromes. Protocol No. 4522US/0001. 2005. Principal Investigator.
13. A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study
of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding
and Symptomatic Ulcer Disease. Protocol No. CG104. 2008. Principal Investigator.
16

Vincent Michael Figueredo, MD, FACC, FAHA

Transcription

Similar documents